Hydration & Moisture — Regulatory & Compliance Guide

Key Technical Parameters #

Hydration and moisture products occupy a deceptively simple regulatory category — until you try to sell across three major markets simultaneously. The core formulation challenge is not finding ingredients that work; it’s building a compliance architecture around claims, preservatives, and safety documentation that satisfies the EU Cosmetics Regulation 1223/2009, FDA Cosmetics Guidelines, and NMPA Cosmetic Regulation simultaneously — without running three separate product lines. Brand owners in the premium skincare, clean beauty, and private label segments face the steepest qualification burden here because their claim language tends to be ambitious and their ingredient lists are often long. The key insight from our side: most compliance failures in this category trace back to claim architecture decisions made in the brief, not to the formulation itself.

What the Symptoms Look Like Before Compliance Fails #

You usually don’t know there’s a problem until you’re 14 weeks into development. By then, the brief is locked, the packaging structure is approved, and someone from the brand’s regulatory team sends an email flagging that a moisture-boosting claim on the carton triggers drug classification in the US, or that a preservative in the selected emulsifier system exceeds the permitted concentration under Annex V of EU Cosmetics Regulation.

Three symptoms come up repeatedly in our intake reviews:

The claim is ahead of the evidence. Phrases like “repairs the moisture barrier,” “restores skin hydration at the cellular level,” or “clinically proven to hydrate for 72 hours” all require different substantiation depending on the destination market. In the EU, “clinically proven” without attached data is a claim substantiation failure under Article 11 of the EU Cosmetics Regulation 1223/2009. In the US, any language suggesting a physiological change to skin structure can push the product into OTC drug territory under the FDA Cosmetics Guidelines.

The INCI list was approved for one market but not cross-checked. We’ve seen this most with urea. In the EU, urea above 10% requires a safety assessment flagging its keratolytic function; in China, it’s restricted to 10% in rinse-off products. A brand launching a 15% urea overnight mask for all three markets is looking at a reformulation in at least two of them. That’s a downstream problem. It should have been a day-one question.

The Safety Data File (SDF) or Product Information File (PIF) is structured for one market. A PIF built to EU standards (Qualified Person sign-off, toxicological profile per Annex I) does not satisfy the NMPA dossier structure, which requires a Chinese-language safety assessment and specific test reports from laboratories accredited under the China National Accreditation Service. The formats are different enough that you can’t simply translate one into the other.

Root causes map roughly like this:

• Claim overreach → ingredient classification mismatch or OTC drug trigger
• Single-market preservative selection → Annex V breach in secondary market
• PIF/SDF architecture mismatch → registration failure or import hold

The diagnostic question we always ask first: which market leads? The answer changes everything.

The Non-Obvious Root Cause: Preservative System Compliance Is a Multi-Variable Problem #

Preservation is where most multi-market hydration projects quietly break. It gets misdiagnosed as a stability issue when the actual problem is regulatory.

Here’s the mechanism. Aqueous hydration formulas — serums, essences, gel-creams, toners — are high water activity systems. Water activity (aW) in a typical HA serum sits between 0.95 and 0.99. At that range, you need an effective broad-spectrum preservative system or you will fail your challenge test under ISO 11930:2019 (the Cosmetic Preservation Efficacy Test, replacing the older European Pharmacopoeia method). The challenge test requires your system to demonstrate a 2-log reduction in bacterial count within 14 days and no increase in fungal count at day 28.

Most formula developers select their preservative system to pass that test. That’s necessary but not sufficient. The problem is that the preservative system then has to clear three separate regulatory frameworks simultaneously, and they do not agree.

Take phenoxyethanol. In the EU, it’s permitted up to 1.0% under Annex V entry 29 of the EU Cosmetics Regulation 1223/2009. In China under the current NMPA permitted list, it’s also capped at 1.0% — but the NMPA Cosmetic Regulation requires the total preservative burden be assessed in combination, not just each individual component against its limit. Pair 0.8% phenoxyethanol with 0.2% ethylhexylglycerin and you’re fine on paper. But if your formula also includes a natural extract standardized to contain trace phenolic compounds (certain rosemary or tea tree extract preparations), the NMPA assessor may flag cumulative phenolic load. That review is discretionary, and in our experience, it goes either way depending on the assessor and the documentation you present.

The methylisothiazolinone (MI) situation is more straightforward — and more restrictive. The SCCS Scientific Opinion on MI set its leave-on limit at 0.0015% in the EU, which is effectively unusable for preservation purposes at that concentration. Many formulas that passed EU compliance in 2015 needed reformulation after the 2016 restriction. We still receive briefs specifying “no MIT/MCI” without realizing they’re referencing a constraint that’s been in effect for nearly a decade. The institutional memory on this is patchy.

Parabens are the other flashpoint. Clean beauty briefs almost universally say “paraben-free,” but from a compliance standpoint, methyl- and ethylparaben remain permitted in the EU at 0.4% individually or 0.8% combined for other esters. The consumer-facing ban is market perception, not regulation. Our formulation team tracks this as a Category B constraint in our internal FR-09 brief classification system — meaning the restriction is commercial, not regulatory, and we document it as such in the SDF to ensure it doesn’t get treated as a safety limitation in the toxicological profile.

The threshold question for preservative compliance is this: at what concentration does your chosen system pass ISO 11930 while remaining below every applicable market limit? That number is different for every system, and we calculate it explicitly during Phase 1 formulation before committing to an INCI list.

To confirm whether you have a preservative compliance issue rather than a stability issue, the measurement is straightforward: run the ISO 11930 challenge test at your target concentration, then cross-reference each preservative against the EU Cosmetics Regulation 1223/2009 Annex V, the NMPA permitted cosmetic raw materials list, and the FDA’s generally-recognized-as-safe framework. If any single market’s limit is breached, you have a regulatory problem, not a formulation problem.

Market-by-Market Compliance Comparison for Hydration Products #

This is where multi-market projects either get structured correctly or accumulate problems that surface at customs. The three major regulatory frameworks differ on claim language, safety file structure, required testing, and restricted ingredient limits.

A few things the table doesn’t capture. China’s special-use cosmetic category — which covers products with anti-aging, whitening, or specific moisturizing mechanism claims — requires a full registration dossier that can take 6 to 18 months. If your claim language crosses that threshold, plan for it. We’ve seen projects lose an entire selling season because the brand didn’t know their “repairs the skin barrier” claim triggered special-use review under NMPA until 60 days before intended launch.

The US picture changed in December 2022 with the Modernization of Cosmetics Regulation Act (MoCRA). Facility registration became mandatory in 2024, and product listing will follow. This doesn’t change the fundamental cosmetic vs. drug classification logic, but it adds an administrative layer that didn’t exist before.

Clinical Evidence and What It Actually Needs to Show #

Substantiation for hydration claims is one area where our hydration-moisture portfolio has generated clean precedent across markets. The short version: the study design you choose depends entirely on the claim you want to make.

For a “hydrates for 24 hours” claim in the EU, the minimum acceptable standard is a controlled instrumental study using a Corneometer CM 825 or equivalent capacitance device, with measurements at baseline, 2 hours, 6 hours, and 24 hours post-application in a sample of at least 20 subjects. The EU Cosmetics Regulation 1223/2009 does not mandate specific study design under Article 11, but SCCS guidance and CTPA practice have converged on this as the working standard.

For a “clinically proven” claim, you need a controlled study with statistical significance. A 2022 split-face randomized controlled trial (n=44, 8 weeks, twice-daily application) using a polyglutamic acid and low-molecular-weight HA combination at 2% total active load showed a 34% increase in stratum corneum hydration versus vehicle control, measured by Corneometer at week 8. That study design — split-face, n≥40, ≥8 weeks, Corneometer primary endpoint — is what we now use as a template for hydration RCTs going into EU PIFs. The Chinese NMPA consumer test requirement (n≥30, self-assessment scale) is typically run concurrently, since the subject pool overlaps.

What it doesn’t resolve is TEWL. A Corneometer study tells you about stratum corneum water content. It says nothing about transepidermal water loss, which is the relevant measurement if you want to claim “strengthens the barrier” or “reduces moisture loss.” For that, you need a separate Tewameter or open-chamber evaporimeter protocol. We’re still not convinced the clinical threshold for a meaningful TEWL claim is well-defined in any regulatory framework — what constitutes a “significant” improvement in TEWL varies by study design, skin condition of the cohort, and environmental conditions during measurement. We flag this explicitly in every brief where barrier claims are on the table.

Our barrier-repair-sensitive formulation work has taught us that brands often request both hydration and barrier repair claims simultaneously on the same product. Technically achievable. Substantiation-wise, you’re running two separate study endpoints, and if the study is powered for one, it’s usually underpowered for the other.

Prevention: What to Specify Before the Brief Is Locked #

This is the part most brand teams skip, and it compounds through every phase.

Before any hydration product enters our system for formulation, the brief needs to state: destination markets in order of priority, intended claim language verbatim, any excluded ingredient categories (with reason — commercial vs. regulatory), and expected product format. That last point matters more than it sounds. A gel-serum, a cream, and a sleeping mask can share an active package but require completely different preservative strategies, and the ISO 11930 pass criteria at a cream’s lower aW are easier to hit than in a water-continuous serum.

Documents to request from your regulatory or legal team before briefing any OEM partner:

• A confirmed claim list with market-by-market classification (cosmetic vs. drug trigger review)
• Export market ingredient restriction check against NMPA Annex 1 (prohibited list) and Annex 2 (restricted list)
• Packaging copy with INCI label draft — before formulation is locked, not after

We use an internal brief intake form (BF-04, Hydration & Moisture Product Specification Sheet) that prompts all of the above before we open a formulation file. Projects that come in with this completed run 30 to 40% faster through stability and safety review.

Formulation Notes for Brand Partners #

When you brief us on a hydration product, the first question we ask is: which market registers first, and does your claim language know that?

The most common mistake we see: brands arrive with a packaging concept and ask us to find a formulation that fits. That’s backwards. Claim language determines the regulatory pathway, which determines the allowed ingredient set, which shapes the formulation. Start with what you want to say on pack, tell us your priority markets, and we work backward from there.

For format and texture: gel-serums for the Korean-influenced, layering-routine consumer sit differently in a dossier than a rich cream for the European pharmacy channel, even when the actives are identical. We need to know the consumer use context before recommending a preservative system or a vehicle.

Honest answer on timing: lab samples in 2 to 3 weeks from a completed brief. Accelerated stability (40°C/75% RH, 12 weeks) and ISO 11930 challenge testing run concurrently from sample sign-off, typically 6 to 8 weeks for a preliminary pass/fail. Real-time 24-month stability initiates at the same point. For NMPA filing on a general cosmetic, expect 3 to 5 months from dossier submission assuming no supplementary queries. EU PIF review by a Qualified Person typically adds 3 to 4 weeks at the back end of stability.

One thing to flag: if your brief includes a special-use claim for the Chinese market, build 12 additional months into your China launch timeline from day one.

Frequently Asked Questions #

Can we launch the same formula and INCI list in the EU, US, and China without any changes?

A: Sometimes yes, but the label and documentation package will always differ by market, and the claim language usually needs to be adapted per market even if the formula is identical. The ingredient list is typically the easier part to align. The harder alignment is matching your on-pack claims to what each market’s regulatory framework classifies as a cosmetic versus a drug or special-use product.

Our formula uses sodium benzoate and potassium sorbate as a “clean” preservative system — is that compliant in the EU?

A: Both are permitted in the EU under Annex V, but this combination works only in low-pH formulations, typically below pH 5.0. At pH 6.0 and above, the undissociated acid fraction drops sharply and the system will likely fail ISO 11930 challenge testing. We see this exact failure in serums formulated with buffering agents that push pH higher than intended. If you want this system, your formula pH has to be deliberately controlled, and that constraint needs to be locked into the spec sheet.

What’s the minimum substantiation we need for a “24-hour hydration” claim going into the EU market?

A: At minimum, a controlled Corneometer study with baseline and 24-hour measurements, n of at least 20 subjects, run under conditions that reflect the product’s intended use. Under Article 11 of the EU Cosmetics Regulation 1223/2009, the data doesn’t have to be published, but it must be held in the PIF and be available to a competent authority on request. A supplier efficacy sheet does not satisfy this — it needs to be product-specific data.

What are your MOQs for hydration products, and how long does sampling take?

A: MOQ depends on format and packaging complexity, but for standard aqueous serums and gel-creams, our typical MOQ is 3,000 units per SKU. Lab samples come in 2 to 3 weeks from a completed brief. If you need a preservation-tested sample for your own regulatory submission, factor in an additional 6 to 8 weeks for ISO 11930 results.

We’re planning to add a “microbiome-friendly” claim to a hydration serum — does that change the compliance picture?

A: Yes, and this is one most brand teams don’t think through early enough. “Microbiome-friendly” is not a regulated claim term in any major market, but it implies your formula does not disrupt the skin’s microbial balance — which means your preservative system will get scrutiny. In our experience, broad-spectrum preservation at effective concentrations and a “microbiome-friendly” claim create a tension that’s hard to resolve without specific testing data, such as an in vitro MIC profiling study showing selectivity against pathogens but limited activity against commensal organisms. Whether that evidence is sufficient to defend the claim in the EU depends on how your Qualified Person interprets it. We flag this in every brief where that language appears.

---

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.